Orion Corporation

Other

Lasse Lehtonen

Saila Antila

Arto Olavi Urtti

Ilkka Larma

Jouni Hirvonen

Maarit Bäckman

Jyrki Lilleberg

Pertti Pentikäinen

Iikka Larma

Mikhail Ruda

Jeffrey Hosenpud

Julius Papp

Janos Szecsi

Levosimendan, or (&#x2212;)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been previously suggested for the treatment of congestive heart failure, is useful in the treatment of erectile dysfunction.

Method for treating erectile dysfunction

The invention relates to peroral pharmaceutical compositions which release levosimendan in a controlled fashion with reduced occurrence of undesired effects. Levosimendan, or (&#x2212;)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile, is useful in the treatment of congestive heart failure.

Controlled release peroral compositions of levosimendan

Levosimendan, or (&#x2212;)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, which has been previously suggested for the treatment of congestive heart failure is useful in the treatment of sick sinus syndrome and/or sinoatrial conduction disorders.

Method of treating sick sinus syndrome with levosimendan

Levosimendan, or (&minus;)-&lsqb;&lsqb;4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl&rsqb;hydrazono&rsqb;-propanedinitrile, which has been previously suggested for the treatment of congestive heart failure is useful in the treatment or prevention of coronary graft vasospasm after coronary artery by-pass surgery.

Method for the treatment or prevention of coronary graft vasospasm

Levosimendan, or (&minus;)-&lsqb;&lsqb;4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl&rsqb;hydrazono&rsqb;-propanedinitrile, which has been previously suggested for tho treatment of congestive heart failure is useful in the treatment of pulmonary hypertension.

Method of treating pulmonary hypertension

A composition for oral administration comprising a substantially pure crystalline polymorphic form (I) of levosimendan as an active ingredient together with a pharmaceutically acceptable carrier is described. Polymorphic form (I) of levosimendan is rapidly absorbed from the gastrointestinal tract and is useful in the treatment of congestive heart disease.

Oral compositions of levosimendan

Transdermal administration of levosimenden or (&minus;)-&lsqb;&lsqb;4-(1,4,5,6-tetahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono&rsqb;propanedinitrile or a pharmaceutically acceptable salt thereof is disclosed. Transdermal preparations of levosimenden can be in the form of e.g. ointment, emulsion, lotion, solution, gel, cream, patch or transdermal delivery device including iontophoretic device.

Growing community of inventors

Espoo, Finland

Lasse Lehtonen